Clinical Trial Update: Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

A phase 1 clinical trial update for CX-4945 (silmitasertib) in relapsed or refractory multiple myeloma conducted by Cylene Pharmaceuticals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CX-4945 (silmitasertib)

Snippet

Sponsor: Cylene Pharmaceuticals | Conditions: Multiple Myeloma | Phase 1 | Status: UNKNOWN